Study of ZG005 in Patients With Advanced Solid Tumors
Interventistico
Fase 2
Sun Yat-sen University Cancer Center
Sponsor: Zelgen Biopharmaceuticals
Ultimo Aggiornamento: 5 gennaio 2026 Avviso - Le informazioni provengono da registri pubblici e potrebbero non riflettere i cambiamenti in tempo reale presso il centro locale.
This is an open-label, multicenter, Phase II clinical trial, designed to evaluate the efficacy and safety of ZG005 in patients with advanced solid tumors who have previously failed or are intolerant to standard treatment.
* Fully understand the study and voluntarily sign the informed consent form.
* Male or female 18-75 years of age;
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1;
* Life expectancy ≥ 12 weeks;
* Histologically or cytologically confirmed diagnosis of advanced solid tumors.
Criteri di Esclusione
* Medical history, computed tomography (CT) or magnetic resonance imaging (MRI) results indicate that existence of the central nervous system(CNS) metastases;
* Any other malignancy within 5 years.
Pensi che questo studio appaia erroneamente?
Dettagli del Disegno
AllocazioneN/A
Modello di InterventoSingle Group Assignment
MascheramentoNone (Open Label)
Numero da Arruolare100
Bracci e Interventi
Bracci
Interventi
Tipo: Experimental
Descrizione: ZG005 dose expansion was performed in different tumors, such as: nasopharyngeal carcinoma, esophageal squamous cell carcinoma, and other carcinoma